Please upgrade your browser.
World experts in the treatment of kidney cancer will gather in London 06 May 2010 to discuss cutting-edge treatments with patients and their family members. Also on the expert panel, a barrister who handles patient appeals to NICE. Travel subsidies for the indigent living in Europe are available. See "Calendar of Events" at http://kidneycancer.org for details.
This informative all-day meeting gave over 40 nurses from across Wales the opportunity to learn more about kidney cancer and improve patient care and their understanding of the disease.
Penn State Football Uplifting Athletes has announced that nine current players will be participating in a dunk tank fundraiser from 5-7 p.m. on Friday (April 23) near Beaver Stadium as part of Blue-White Weekend presented by AAA.
Previous studies have found associations between one-carbon metabolism factors and risk of several cancers, but little is known regarding renal cell carcinoma (RCC). We conducted a nested casecontrol study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a prospective study of Finnish male smokers aged 5069 at baseline.
Ask Dr. Anthony Ciarallo a Question Regarding Adult Renal Cell (Kidney) Cancer [forum section]
He et al also established primary renal cell carcinoma cultures from fresh human tumor biopsies which were ASS-deficient. ADI-PEG 20 inhibited growth of these cells. These findings suggest that ASS deficiency may serve as a biomarker for selecting tumors for targeted therapy with ADI-PEG 20.
These findings illustrate the mechanism for the release of cysteine-mcMMAF after internalization of the ADC into target cells (Abstract #5334). SGN-75 is in an ongoing phase I clinical trial for CD70-positive relapsed/refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma.
Is it a tool or a toy? You can decide. Bear in mind, no two cases are exactly alike.
MethylGene Presents Preclinical Data for MGCD265 (A Multi-Targeted Met Kinase Inhibitor) at the American Association for Cancer Research (AACR) Annual Meeting
MGCD265 is an oral multi-targeted receptor tyrosine kinase inhibitor currently in multiple clinical trials. MGCD265 targets Met and blocks Met activities which contribute to cancer development and progression such as cell proliferation, motility, angiogenesis and tumor cell survival.
EORTC releases results of 30904 study on kidney cancer.
|NeonCRM by Neon One|